A methodologically weak negative study
may harm the science more as compared to the methodologically weak positive study.
This study is a large and rigorous negative study
, and we must judge whether it can tip the balance of probiotic evidence.
From a regulatory perspective and the narrow viewpoint of regulatory approval, this is a negative study
But I believe that from a scientific point of view, this is an extremely interesting study, and clinically potentially very important.
When negative reports on supplements come out, Nature Made says it provides research overviews explaining the negative study
and puts detailed findings into context with its sales team, which shares information with retailers, retail dietitians and pharmacists, among others.
Hauser, Department of Neurology Chair at University of California, San Francisco and Editor-in-Chief of Annals adds, "In the end, CombiRx was essentially a negative study
, with the combination therapy doing no better than monotherapy in reducing MS relapse rate over three years.
Despite the negative study
findings and the reviews, and despite a warning letter from the FDA to at least one commercial center promoting unproven uses, one can still find HBO being advertised as a therapy for MS.
According to the government's complaint, Forest allegedly marketed certain drugs for off-label pediatric use when they had been approved for adult use only by, among other things, disseminating positive study results on pediatric use while failing to disclose the negative study
results for the same pediatric use.
When you see a negative study
[about the effect of treating mental disorders in a pregnant woman], keep in mind that there is often a lack of information about the mother's diagnosis.
Dr Gibbs implies that the P value of a positive study, or the power of a negative study
, can be used to determine a definitive likelihood that a result reflects reality.
He adds that this is one negative study
that should be viewed in the context of the overall body of research regarding heart-brain health.
It will be viewed as a largely negative study
and people who are enthusiasts for omega fatty acids will continue to be enthusiasts and people who are sceptics will continue to be sceptics," said Scott Wright of the Mayo Clinic in the United States, who was not involved in the research.
Wedbush Securities analyst Liana Moussatos reaffirmed a "Neutral" rating on the stock with a $15 price target, but said the negative study
results could push shares below $5.